

**Brilliant Violet 510™ anti-human CD69**

**Catalog # / Size:** 2154680 / 100 tests  
2154675 / 25 tests

**Clone:** FN50

**Isotype:** Mouse IgG1, κ


**Reactivity:** Human

**Preparation:** The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 510™ under optimal conditions. The solution is free of unconjugated Brilliant Violet 510™ and unconjugated antibody.

**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

**Workshop Number:** IV A91

**Concentration:** Lot-specific



Human peripheral blood lymphocytes were stimulated with PMA+ ionomycin for 6 hours and then stained with CD69 (clone FN50) Brilliant Violet 510™ (filled histogram) or mouse IgG1, κ Brilliant Violet 510™ isotype control (open histogram).

**Applications:**

**Applications:** Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 510™ excites at 405 nm and emits at 510 nm. The bandpass filter 510/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. **Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel.** Refer to your instrument manual or manufacturer for support. Brilliant Violet 510™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

**Application Notes:** Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections<sup>2</sup> and immunofluorescence microscopy<sup>3</sup>.

**Application References:**

1. Knapp WB, *et al.* 1989. Leucocyte Typing IV. Oxford University Press. New York.
2. Sakkas LI, *et al.* 1998. *Clin. and Diag. Lab. Immunol.* 5:430. (IHC)
3. Kim JR, *et al.* 2005. *BMC Immunol.* 6:3. (IF)
4. Verjans GM, *et al.* 2007. *P. Natl. Acad. Sci. USA* 104:3496.

5. Lu H, *et al.* 2009. *Toxicol Sci.* 112:363. (FC) [PubMed](#)
  6. Thakral D, *et al.* 2008. *J. Immunol.* 180:7431. (FC) [PubMed](#)
  7. Yoshino N, *et al.* 2000. *Exp. Anim. (Tokyo)* 49:97. (FC)
- 

**Description:** CD69 is a 27-33 kD type II transmembrane protein also known as activation inducer molecule (AIM), very early activation antigen (VEA), and MLR3. It is a member of the C-type lectin family, expressed as a disulfide-linked homodimer. Other members of this receptor family include NKG2, NKR-P1 CD94, and Ly49. CD69 is transiently expressed on activated leukocytes including T cells, thymocytes, B cells, NK cells, neutrophils, and eosinophils. CD69 is constitutively expressed by a subset of medullary mature thymocytes, platelets, mantle B cells, and certain CD4<sup>+</sup> T cells in germinal centers of normal lymph nodes. CD69 is involved in early events of lymphocyte, monocyte, and platelet activation, and has a functional role in redirected lysis mediated by activated NK cells.

**Antigen**  
**References:** 1. Schlossman S, *et al.* Eds. 1995. *Leucocyte Typing V.* Oxford University Press. New York.

2. Testi R, *et al.* 1994. *Immunol. Today* 15:479.